NCT07358013 Endothelial Colony-Forming Cells in Patients With VWD, AVWS and Healthy Subjects
| NCT ID | NCT07358013 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico |
| Condition | Von Willebrand Disease (VWD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 48 participants |
| Start Date | 2023-11-11 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 48 participants in total. It began in 2023-11-11 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn how endothelial colony-forming cells (ECFCs) behave in people with von Willebrand disease (VWD), acquired von Willebrand syndrome (AVWS), and in healthy individuals.
Eligibility Criteria
Inclusion Criteria for patients: Patients with von Willebrand disease (VWD) or acquired von Willebrand syndrome (AVWS) Age ≥ 16 years. Previous diagnosis of von Willebrand disease or acquired von Willebrand syndrome, defined as one of the following: Group A - Type 1 VWD: VWF levels ≤ 30 IU/dL, regardless of bleeding history, or VWF levels ≤ 0.50 IU/mL in the presence of abnormal bleeding. Group B - Congenital or acquired VWD (VWD or AVWS): Diagnosis of congenital or acquired VWD, with or without gastrointestinal bleeding. Group C - Subgroup study (Type 2A VWD): One patient with type 2A VWD selected for a dedicated sub-study involving allele-specific siRNA silencing of the mutant allele. Ability and willingness to provide written informed consent. For patients without prior molecular characterization: willingness to undergo VWF gene sequencing and to sign the related informed consent. Inclusion criteria for healthy volunteers * No prior diagnosis of VWD, bleeding disorders, or thrombotic disorders. * Willingness to donate blood for study procedures. * Ability and willingness to provide written informed consent. * Age ≥ 18 years. Exclusion criteria for both patients and healthy volunteers: * Pregnancy. * Anemia, as determined at screening or based on medical history.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07358013 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, studying Von Willebrand Disease (VWD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07358013 currently recruiting?
Yes, NCT07358013 is actively recruiting participants. Contact the research team at flora.peyvandi@policlinico.mi.it for enrollment information.
Where is the NCT07358013 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT07358013 clinical trial?
NCT07358013 is sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. The trial plans to enroll 48 participants.